News zu Abionyx Pharma

ABIONYX Pharma Announces Its 2024 Full-Year Results · Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2024 · Uhr · Business Wire
ABIONYX Pharma Announces Its 2024 Half-Year Financial Results · Uhr · Business Wire
ABIONYX Pharma: Clarification About Clinical Results From the Phase 3 of apoA-I study, CSL112 · Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Activity, Its Revenue and Its Cash Position for the Third Quarter of 2023 · Uhr · Business Wire
ABIONYX Pharma Completes a Capital Increase in Favor of Categories of Persons · Uhr · Business Wire
ABIONYX Pharma Announces Its 2023 Half-Year Financial Results · Uhr · Business Wire
World Sepsis Day September 13, 2023: ABIONYX Pharma Confirms Its Commitment to Sepsis, a Global Public Health Issue · Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Half of 2023 · Uhr · Business Wire
ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess · Uhr · Business Wire
ABIONYX Pharma Announces the Appointment of Laurent Guerci as Chief Digital & Innovation Officer · Uhr · Business Wire
ABIONYX Pharma Announces a New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe · Uhr · Business Wire
ABIONYX Pharma Announces Unanimous Approval of All Resolutions Put to the Vote at Its Combined General Meeting · Uhr · Business Wire
ABIONYX Pharma Provides Further Details on the Setting up of Its Equity-Linked Financing Facility · Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Activity and Its Cash Position for the First Quarter 2023 · Uhr · Business Wire
ABIONYX Pharma Announces Its Strategy in Ophthalmology and New Positive Preclinical Results for the Deployment of Two Innovative Technology Platforms: Apotherapy and Biovectorization · Uhr · Business Wire
ABIONYX Pharma Announces Its 2022 Full-year Financial Results · Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Activity and Its Cash Position for the 4th Quarter 2022 · Uhr · Business Wire
ABIONYX Pharma: Press Release · Uhr · Business Wire
ABIONYX Pharma Announces Its Financial Agenda for the Year 2023 · Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Half Of 2022 · Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Quarter of 2022 · Uhr · Business Wire
ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects · Uhr · Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital · Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Business and Cash Position for Q4 2021 · Uhr · Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital · Uhr · Business Wire
ABIONYX Pharma Announces Its Financial Agenda for the Year 2022 · Uhr · Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital · Uhr · Business Wire
ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease · Uhr · Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital · Uhr · Business Wire
ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts... · Uhr · Business Wire
ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3.60 Per Share · Uhr · Business Wire
ABIONYX Announces the Signing of an Agreement for the Contribution of 100% of the Capital of IRIS Pharma Holding, Fully Remunerated by the Issuance of New ABIONYX Shares at a Fixed Price of 3.60 Euros per Share · Uhr · Business Wire
ABIONYX Announces New Positive Clinical Results for CER-001 in kidney disease associated with LCAT deficiency Published in The Journal of Internal Medicine · Uhr · Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital · Uhr · Business Wire
ABIONYX Pharma Announces Its Cash Position and Provides an Activity Update for the 3rd Quarter 2021 · Uhr · Business Wire